# Nelfinavir Mesylate in Treating Patients With Kaposi Sarcoma

> **NCT03077451** · PHASE2 · COMPLETED · sponsor: **AIDS Malignancy Consortium** · enrollment: 36 (actual)

## Conditions studied

- Recurrent Kaposi Sarcoma
- Skin Kaposi Sarcoma

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Nelfinavir Mesylate

## Key facts

- **NCT ID:** NCT03077451
- **Lead sponsor:** AIDS Malignancy Consortium
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-13
- **Primary completion:** 2022-05-23
- **Final completion:** 2023-04-13
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2025-12-17

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03077451

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03077451, "Nelfinavir Mesylate in Treating Patients With Kaposi Sarcoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03077451. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*